ReachMD
Be part of the knowledge.™Episodes 31-45 of 97
Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
MinuteCE®Comparing In-hospital Mortality With Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate
Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
MinuteCE®Andexanet Alfa Is Associated With Lower In-Hospital Mortality Compared to 4-Factor Prothrombin Complex Concentrate in Patients With Factor Xa Inhibitor–Related Major Bleeding
Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
MinuteCE®Life-Threatening Bleeding in the Anticoagulated Patient: Real World Evidence
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
CME/CEUnderstanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease – Neurology Module
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
CME/CEUnderstanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Emergency Medicine Module
Understanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
CME/CEUnderstanding the Fine Print: The Who, When, And What To Do About ARIA in Patients with Alzheimer’s Disease - Closing Module
Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
MinuteCE®Reversal of Factor Xa Inhibitor ICH: ANNEXA-4, ANNEXA-I and Real-World Evidence
Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
MinuteCE®Repletion or Reversal? Optimizing Specific Therapy for Direct Oral Anticoagulant (DOAC)-Related Life-Threatening Bleeding Using Real-World Experience
Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
MinuteCE®Reinforcement of Principles, Overcoming Treatment Barriers, and Improving Time to Treatment for ICH
Repletion Management for Vitamin K Antagonist Anticoagulation
MinuteCE®Repletion Management for Vitamin K Antagonist Anticoagulation
Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
MinuteCE®Specific Reversal Therapy for Factor Xa and Factor IIa Inhibitor-Associated ICH Life-Threatening Bleeding
Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
MinuteCE®Case Presentation: Management of a Patient With Factor Xa-Associated ICH Using Specific Reversal Therapy
Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
MinuteCE®Case Presentation: Management of ICH in the Anticoagulated Patient Using Specific Reversal Therapy: Importance of Timing
